Biotech One pitches EncapX® to France BioLead members
5 November 2026
As a member of France BioLead, Biotech One was due to pitch EncapX® on 6 November, during an exclusive session with other France BioLead members.
The ambition stated for that session is to bridge R&D formulation and industrial bioproduction, in support of scalable liposome and LNP manufacturing for next-generation therapies.
The company said it would use the session to present the work and to look for collaborations inside the France BioLead community.
Related news
EncapX® presented at the AFSSI webinar
A liposome and LNP formulation platform using supercritical CO₂, to protect fragile molecules and bridge R&D and industrial production.
26 October 2026
EncapX® on stage at World Vaccine Congress Europe 2026
Exhibitor in the Start-up Zone (booth SU3). Talk by Dr Elissandro Klein on continuous scCO₂ processing for vaccine delivery.
21 October 2026 · RAI Amsterdam
Poster at the Festival of Biologics, Basel
Elissandro Klein presents a poster on the continuous production of lipid-based nanoparticles using supercritical CO₂ (EncapX®).
9 October 2026 · Basel